ANGES, INC.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 1999-12-17
- Employees
- 145
- Market Cap
- -
- Website
- http://www.anges.co.jp
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)
Phase 1
Completed
- Conditions
- COVID-19 Lower Respiratory Infection
- Interventions
- Biological: AG0302-COVID19 for Intramuscular InjectionBiological: AG0302-COVID19 for Intradermal Injection
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- AnGes, Inc.
- Target Recruit Count
- 422
- Registration Number
- NCT04993586
- Locations
- π―π΅
IUHW Narita Hospital, Narita, Chiba, Japan
π―π΅Medical Corporation Heishinkai OCROM Clinic, Suita, Osaka, Japan
π―π΅Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Group A (Placebo)Biological: Group B (AG0302-COVID19)Biological: Group B (Placebo)Biological: Group A (AG0302-COVID19)
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- AnGes, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04655625
- Locations
- π―π΅
Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic, Shibuya-ku, Tokyo, Japan
π―π΅Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan
π―π΅Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Tokyo, Japan
Study of COVID-19 DNA Vaccine (AG0302-COVID19)
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AG0302-COVID19
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- AnGes, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04527081
- Locations
- π―π΅
Osaka University Hospital, Osaka, Japan
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AG0301-COVID19
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- AnGes, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04463472
- Locations
- π―π΅
Osaka City University Hospital, Osaka, Japan
AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain
Phase 1
Completed
- Conditions
- Degenerative Disc Disease
- Interventions
- Drug: AMG0103Drug: Placebo
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- AnGes, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT03263611
- Locations
- πΊπΈ
Florida Medical Pain Management, Saint Petersburg, Florida, United States
πΊπΈUniversity of California San Diego, San Diego, California, United States
πΊπΈSpine Institute of San Diego, San Diego, California, United States
Β© Copyright 2025. All Rights Reserved by MedPath